25 / 51
Page 81
Journal of Clinical Immunology and Allergy
ISSN: 2471-304X
E u r o p e a n C o n g r e s s o n
Vaccines & Vaccination
and Gynecologic Oncology
Vaccines & Vaccination and Gynecologic Oncology 2018
O c t o b e r 2 6 - 2 7 , 2 0 1 8
B u d a p e s t , H u n g a r y
H
uman herpesviruses (HHV1-8) have co-evolved through a persistent infection in the host, spread efficiently to others generally
without causing serious disease. The complex interplay between host and virus has made it difficult to elaborate useful vaccine
strategies to protect against the HHV-associated diseases. The Varicella-Zoster vaccine represents the paradigm of a successfully
marketed herpesvirus vaccine. Over the years, the development of HHV vaccines has been a story of mixed fortunes, especially for
HSV-2 and HCMV. However, studies carried out in various disease settings (i.e. transplant patients or pregnant women), have em-
phasized the importance of cellular immunity and it is indeed encouraging to see that recent HHV vaccine (i.e. HCMV) development
programs have started to incorporate this arm of the immune system. Nowadays, an array of arguments calls for a realistic goal for
vaccine strategies which should be preventing HHV disease rather than HHV infection. It is particularly, the case for the Epstein-Barr
virus (EBV or HHV4) which is the primary cause of infectious mononucleosis and is associated with epithelial cell carcinomas, as well
as lymphoid malignancies. The challenge is that the HHVs express very different proteins during their lytic and latent phases. Parallel
to this need, one could propose priorities for future research: identification of surrogate markers that predict the development of HHV
diseases or malignancies; determination of immune correlates of protection against HHV infection and disease in animal models and
in humans. Finally, we will discuss recent works showing the beneficial role of these persisting viruses in the context of malignancies.
Emmanuel.drouet@ibs.frHuman herpesviruses: should we still invest in
vaccines or focus on predictive tests?
Emmanuel Drouet
Université Grenoble-Alpes, France
Journal of Clinical Immunology and Allergy, Volume: 4
DOI: 10.21767/2471-304X-C2-006
Euro Vaccines 2018